Business
Mesoblast holds out hope for heart failure drug – Sydney Morning Herald
Shares in the stem cell treatment developer regained some ground after a horror end to 2020.
Shares in stem cell biotech Mesoblast jumped nearly 16 per cent after the company said it would pursue approval for its key heart failure drug in the US despite a clinical trial delivering mixed results.
On Monday the company told investors that additional data from the phase 3 trial of its Revascor product showed a “substantial and durable reductions in heart attacks, strokes and cardiac deaths” in patients with chronic heart failure.
Mesoblast shares bounced after a tough end to 2020, when shares…
-
General9 hours agoAlleged Croydon Park gunman Artemios Mintzas charged with 25 offences
-
Noosa News23 hours agoProtest calls for shark net removal
-
General23 hours agoThree youths in police custody after fire at Ashley Youth Detention Centre in northern Tasmania
-
General15 hours agoTeam Australia wins back-to-back Motocross of Nations titles